DanaERathkopfMD

Genitourinary Oncology

Associate Professor, Medicine, Memorial Sloan Kettering Cancer Center

Overview of Dr. Rathkopf

Dr. Dana Rathkopf is an oncologist in New York, NY and is affiliated with multiple hospitals in the area, including Memorial Sloan Kettering Cancer Center, NYC Health + Hospitals / Bellevue, and New York-Presbyterian Hospital. She received her medical degree from Tulane University School of Medicine and has been in practice 19 years. Dr. Rathkopf accepts several types of health insurance, listed below. She is one of 497 doctors at Memorial Sloan Kettering Cancer Center and one of 64 doctors at NYC Health + Hospitals / Bellevue who specialize in Oncology. She has more than 100 publications and over 500 citings.

Office
353 East 68th Street
New York, NY 10065
Book by Phone+1(818) 306-5906

Education & Training

Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2002 - 2005
NYU Grossman School of MedicineResidency, Internal Medicine, 1998 - 2002
Tulane University School of MedicineClass of 1998

Certifications & Licensure

FL State Medical License 2021 - Present
CT State Medical License 2023 - 2025
NJ State Medical License 2021 - 2025
NY State Medical License 2000 - 2025
American Board of Internal Medicine Medical Oncology

Clinical Trials

Docetaxel With Rapid Hormonal Cycling As A Treatment For Patients With Prostate Cancer Start of enrollment: 2003 Jul 01
Docetaxel With Rapid Hormonal Cycling as a Treatment for Patients With Prostate Cancer Start of enrollment: 2003 Jul 01
Completed
Phase 2
Cixutumumab and Temsirolimus in Treating Patients With Metastatic Prostate Cancer Start of enrollment: 2009 Oct 01
Completed
Phase 1, Phase 2
Safety, Pharmacokinetic and Proof-of-Concept Study of ARN-509 (Apalutamide) in Castration-Resistant Prostate Cancer (CRPC) Start of enrollment: 2010 Jul 01
Active, not recruiting
Phase 1, Phase 2
Study to Assess Safety and Tolerability of Oral CC-115 for Patients With Advanced Solid Tumors, and Hematologic Malignancies. Start of enrollment: 2011 Apr 25
Completed
Phase 1
Androgen Deprivation Therapy Prior to Prostatectomy for Patients With Intermediate and High Risk Prostate Cancer Start of enrollment: 2012 Feb 01
Active, not recruiting
Not Applicable
Dual mTOR Inhibitor MLN0128 in Advanced Castration-Resistant Prostate Cancer (CRPC) Patients Start of enrollment: 2014 Mar 01
Completed
Phase 2
ARN 509 Plus Everolimus in Men With Progressive Metastatic Castration-Resistant Prostate Cancer After Treatment With Abiraterone Acetate Start of enrollment: 2014 Apr 01
Completed
Phase 1
Use of an Experimental Drug, CC-115, With Enzalutamide in Men With Castration-Resistant Prostate Cancer Start of enrollment: 2016 Jul 01
Completed
Phase 1
Join now to see all

Publications & Presentations

PubMed

2 citations
Intensification Approaches and Treatment Sequencing in Metastatic Castration-resistant Prostate Cancer: A Systematic Review.
Edoardo Francini, Neeraj Agarwal, Elena Castro, Heather H Cheng, Kim N Chi
European Urology. 2025-01-01
Androgen Deprivation Therapy Drives a Distinct Immune Phenotype in Localized Prostate Cancer.
Matthew C Dallos, Aleksandar Z Obradovic, Patrick McCann, Nivedita Chowdhury, Aditya Pratapa
Clinical Cancer Research. 2024-11-15
Management of Patients with Advanced Prostate Cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC).
Silke Gillessen, Fabio Turco, Ian D Davis, Jason A Efstathiou, Karim Fizazi
European Urology. 2024-10-10

Lectures

An open label phase 1/2A study to evaluate the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of TRC253, an androgen receptor antagonist, in pati...
2019 ASCO Annual Meeting - 6/1/2019
c15-160: Enzalutamide (ENZA) plus CC-115 in men with metastatic castration-resistant prostate cancer (mCRPC): A phase 1b Prostate Cancer Clinical Trials Consortium study.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018

Press Mentions

New SU2C Teams Accelerate Clinical Trials for Difficult Breast & Prostate CancersSeptember 16th, 2019
Prostate Cancer Clinical Trial: What to ExpectJune 9th, 2016
ASCO GU 2020: Treatment Selection in CSPC: Considerations Now and Downstream in an Evolving Therapeutic Landscape (Discussion of Abstracts 82 and 162)February 16th, 2020
Join now to see all

Insurance Accepted

Aetna Choice POS II
BCBS Blue Card PPO
BCBS Illinois PPO
BCBS Minnesota Blue Cross Accord
BCBS New Mexico PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPO
Empire BCBS HMO
Empire BCBS PPO
First Health PPO
Great West PPO
Humana ChoiceCare Network PPO
Lovelace Health Plan PPO
Multiplan PHCS PPO
Multiplan PPO
MVP Healthcare PPO
Oxford Health Freedom
Oxford Health Liberty
Presbyterian Commercial
QualCare HMO
QualCare PPO
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO
WEA Trust Preferred Provider Plan - Trust Pref
Please verify your coverage with the provider's office directly when scheduling an appointment